Hydrix auditor flags going concern uncertainty after wider FY26 loss

Auditor flags material uncertainty over Hydrix’s future funding

Hydrix Limited (ASX:HYD) finished FY26 with an awkward combination of commercial momentum and financial fragility. The engineering and medical technology group secured $11.7 million of new contracts, but revenue fell to $9.74 million, operating cash outflow increased to $1.91 million and its loss before tax widened to $6.72 million.

Grant Thornton did not qualify its audit opinion, but highlighted a material uncertainty related to going concern. Hydrix had current liabilities exceeding current assets by $8.57 million at 30 June, while its cash balance stood at $2.96 million. The directors say shareholder support, proposed debt conversions, extended maturities and forecast cash flows support the going-concern basis, although the forecasts remain contingent on future events.

The balance sheet has since gained some breathing room. Hydrix raised $5.2 million in cash through its entitlement offer by year-end, against gross proceeds of $5.88 million before transaction costs, and secured commitments to convert $3.9 million of debt into equity. That conversion would involve the issue of 784 million additional shares at $0.005, subject to shareholder approval, on top of the 1.18 billion shares issued during the offer. The arithmetic is straightforward: the capital structure has been simplified, but existing shareholders face substantial dilution.

Contract wins rose while revenue and cash conversion weakened

Hydrix Services signed $11.7 million of new work during the year, up from $9.9 million in FY25, with more than 15 active client programs carrying an estimated aggregate value above $37 million. The largest disclosed wins included a $3.4 million Remedy Robotics program for safety-critical software and embedded electronics, a $2.5 million SynCardia contract supporting its Emperor artificial heart and a $1.2 million NIOA program for a counter-UAS subsystem. The Remedy engagement had been detailed in the Remedy Robotics contract earlier in the year.

That order book did not translate into higher FY26 revenue. Services revenue slipped to $9.7 million from $10.1 million, partly because SynCardia’s Emperor program paused temporarily after a change in its funding situation. Hydrix said new projects won late in the second half began replacing that work in the September quarter, but the timing of customer funding and project starts remains important to the group’s cash profile.

Australian defence contracts contributed $2.9 million of sales, representing 70% of Australian revenue, while 73% of total Services revenue came from outside Australia. The figures show a business with international reach and a growing defence footprint, but not yet one converting its contract pipeline into reliable operating profitability.

Hydrix Defence targets ownership beyond engineering fees

Hydrix established Hydrix Defence in May 2026 to pursue acquisitions, licences and development opportunities in sovereign defence technology. Its stated areas of interest include sensing, autonomy, electronic warfare, navigation in GPS-denied environments and counter-UAS systems.

The strategy is a step beyond project-based consulting: Hydrix wants to retain more economic value in technologies it helps develop through intellectual property ownership, licensing, production and support. The company’s defence IP strategy had previously outlined a focus on sensing and autonomous systems. For now, however, the annual report records a strategy and a set of contracted programs rather than material recurring revenue from owned defence assets.

Singapore contract adds a medical commercialisation test

Hydrix Medical signed a three-year contract after year-end with Singapore’s National Heart Centre for its Implicity remote cardiac monitoring platform, valued at approximately A$0.625 million. The agreement was not part of FY26 revenue, and Hydrix says implementation, reimbursement and procurement pathways can make healthcare sales cycles lengthy.

The contract gives Hydrix a major regional reference site, according to the company, and follows the Singapore heart centre contract announced in September. The immediate financial contribution is modest relative to the group’s funding needs; the larger question is whether the deployment helps convert other hospital prospects into paying customers.

Investment write-down deepens statutory loss

Hydrix’s Ventures portfolio fell sharply in reported value, from $3.17 million to $415,732. A $2.3 million mark-to-market reduction in its Gyder Surgical investment was the main factor, while Wavewise Analytics was also revalued lower after a capital raising. Hydrix separately wrote its Avertix Medical investment down to nil after the US company entered liquidation proceedings.

These fair-value movements were non-cash, but they still pushed the statutory loss materially higher. Excluding fair-value losses, Hydrix reported an adjusted loss before tax of $3.96 million, compared with $3.19 million in FY25. Management’s FY27 objective is to reach cash operating profit through higher revenue, margins and utilisation alongside lower operating costs. The test will be whether the new contracts arrive quickly enough, and at sufficient margin, to close that gap before further funding becomes necessary.